Loading
  • Pipeline Pipeline
    • Pipeline Chart
    • uPAR-targeted radiopharmaceuticals
    • MNPR-101
      • Overview
      • Development Strategy
      • SNMMI Poster June 2024
      • EANM Presentation October 2024
    • Collaborations
      • Overview
      • Current Collaborations
    • Publications
      • MNPR-101
    • ALXN1840
      • EASL Poster May 2025
  • Investors Investors
    • Overview
    • Annual Meeting
    • News / Events
      • Press Releases
      • IR Calendar
      • In the News
      • Email Alerts
    • Company Information
      • Profile
      • Presentations
      • Our Team
      • FAQ
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
  • Our Team Our Team
  • Careers Careers
  • Contact Us Contact Us
  • Home
  • Investors
  • News / Events
  • Press Releases
Investors

Investors

  • Overview
  • Annual Meeting
  • News / Events
    • Press Releases
    • IR Calendar
    • In the News
    • Email Alerts
  • Company Info
    • Profile
    • Presentations
    • Our Team
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • In the News
  • Email Alerts

Press Releases

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Apr 29, 2025

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Mar 31, 2025

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Dec 20, 2024

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Dec 5, 2024

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Dec 3, 2024

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Nov 8, 2024

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Oct 30, 2024

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Oct 28, 2024

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Oct 28, 2024
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...12
  • About
  • Pipeline
  • Investors
  • Our Team
  • Careers
  • Contact Us
  • Pipeline
  • Pipeline Chart
  • uPAR-targeted radiopharmaceuticals
  • MNPR-101
  • Collaborations
  • Publications
  • ALXN1840
  • Investors
  • Overview
  • Annual Meeting
  • News / Events
  • Company Information
  • Stock Data
  • SEC Filings
  • Corporate Governance

Terms and Conditions of Use

© 2025 Monopar Therapeutics Inc. All Rights Reserved.